Pharmaceutical Sector

Ranbaxy gets nod for marketing the generic amlodipine tablets in Japan

Ranbaxy Laboratories, India's largest pharmaceutical company, has received authorization from Ministry of Health and Labour Welfare of Japan for marketing the generic version of amlodipine tablets of 2.5mg and 5mg, used in the treatment of high blood pressure.

Amlodipine is the first independent product approval received by company in Japan and also has the distinction of being the first product developed by any foreign generic pharmaceutical company outside Japan and subsequently being granted approval by the Japanese Government.

Ranbaxy enters into a collaborative research agreement with DBT

India'a largest pharmaceutical company Ranbaxy Laboratories Ltd has entered into a collaborative research agreement with the Department of Biotechnology (DBT), New Delhi, in the area of New Drug Discovery Research (NDDR).

The research will be conducted under the aegis of DBT's major initiative in the area of tuberculosis and three major areas identified in the program are: - Development of Diagnostics - Development of Vaccines - Development of Drugs.

Under the alliance, Ranbaxy will develop novel drugs, using inhibitor design for novel targets / pathways /proteins etc.

Suven Life Sciences inks strategic alliance with VPSCRO; Stock up 9%

Suven Life Sciences inks strategic alliance with VPSCRODrug-maker Suven Life Sciences Ltd has informed that its clinical research division Asian Clinical Trials (ACT) has entered into a strategic alliance with VPSCRO, a CRO based in Beijing, China to conduct clinical trial services in India, as well as in China.

This strategic alliance between ACT and VPSCRO will allow the company to offer compressive range of clinical services to global sponsors with the state of the art infrastructure, network of trained investigators in India and China by leveraging their expertise to the conduct quality clinical research.

Ranbaxy’s Group Company Picks 9.54% Stake In Orchid Chemicals

Solrex Pharmaceutical Co, which belongs to Ranbaxy Labs or its founders, Ranbaxy managing director and CEO Malvinder Singh has bought 9.54% stake in Chennai-based Orchid Chemicals & Pharmaceuticals.

A creeping acquisition has commenced in the shares of Orchid, which has become vulnerable to acquisition after its share price fell sharply during the last month.

Kailasam Raghavendra Rao, Orchid founder and managing director, stated that he was fixed to retain control over the company and would depend upon support from institutional investors. But his alternatives could be limited, since he possesses only 17%.

Jubilant Organosys plans to buy Draxis Health for US$ 255 million

Jubilant Organosys, an India-based integrated pharmaceuticals industry player, has informed that it will buy 100% stake in Canadian drug producer Draxis Health Inc. through its wholly-owned subsidiary for US$ 255 million (Rs 1,020 crore).

Draxis Health sells sterile products including liquid and freeze-dried injectables and sterile ointments and creams; non-sterile products like solid oral and semi-solid dosage forms; and radiopharmaceuticals. The company, with it current strength of 500 employees, has its manufacturing operations in Montreal.

Ranbaxy launches “BONISTA-Teriparatide Inj” for Osteoporosis patients

Ranbaxy Laboratories, Country's largest drug maker, has announced the launch of BONISTA- Teriparatide injection (recombinant human parathyroid hormone) for the treatment of Osteoporosis, in collaboration with Virchow Biotech Pvt. Ltd. Hyderabad, India.

Osteoporosis is highly prevalent in India. An estimated 61 million people in India are reported to be affected by it.

Ranbaxy is the first Company to launch this bio generic product in the world. The product has been indigenously researched at Virchow Biotech and developed with and from the Department of Science and Technology, Government of India.

Dr. Reddy's acquires Italian firm, Jet Generici Sri

Dr. Reddy's Laboratories Ltd., India's second-largest drug-maker, has informed that the company has acquired Jet Generici Sri, a company engaged in the sale of generic finished dosages in Italy.

The deal has been completed via Dr Reddy’s Italian subsidiary, Reddy Pharma Italia SpA, which has been engaged in building a pipeline of registrations since its incorporation.

The company expects that the present acquisition will provide access to an essential product portfolio, a pipeline of registration applications, and a sales and marketing organisation.

However, the financial terms and conditions of the transaction are not being disclosed.

Dr Reddy’s Labs to acquire stake in UK-based Dowpharma

Dr Reddy’s Laboratories, country's second-biggest drug-maker, has entered into a definitive agreement with the Dow Chemical Company to acquire a portion of Dowpharma’s Small Molecules business associated with its United Kingdom sites in Mirfield and Cambridge.

Dowpharma is a diversified chemical company. It has a global presence in pharmaceuticals, fresh water, food, paints, packaging and personal care products. The company has registered annual sales of US$ 53.5 billion in 2007.

The acquisition will include the relevant business, customer contracts, associated products, process technology, intellectual property, trademarks as well as the transfer of the facilities at Mirfield and Cambridge in the United Kingdom.

Shilpa Medicare acquires 100% stake in LOBA Feinchemie

Shilpa Medicare Ltd., the manufacture and exporter of bulk drugs, has informed that the company has purchased 89,540 shares which comprises 99.99% share in LOBA Feinchemie, Vienna, an Austrian company.

These shares have been bought by Shilpa Medicare through its subsidiary ZATORTIA Holdings Ltd., Limmasol, Cyprus.

LOBA is an ISO 9001 certified company, approved by Austrian Ministry of Health and US Food & Durg Administration (FDA) for GMP production of APIs.

Shilpa Medicare engages in manufacturing and exporting pharmaceutical products. It provides active pharmaceutical ingredients, fine chemicals, intermediates, oncology products, herbal products, and specialty chemical products, as well as bulk drugs and non-oncology products.

Sun Pharma Rolls Out Generic Amifostine For Injection 500mg

Drug manufacturer Sun Pharmaceutical Industries has made announcement about the launching of the generic Amifostine for injection 500mg, which is therapeutically equivalent to MedImmunne’s Ethyol.

Sun Pharma’s product is being sold in the US market through its marketing partner Caraco Pharmaceutical Laboratories. In US, Ethyol has yearly sales of around USD 80 million.

The company has got USFDA nod for marketing the generic Ethyol, used for cancer treatment, on March 17.

Sun Pharma, being the first-to-file an ANDA for generic Ethyol® with a para IV certification, had a 180-day marketing exclusivity.

Ethyol® is covered under 3 patents - ‘471 (July 31, 2012), ‘731 (July 31, 2012) and ‘409 (Dec 8, 2017).

Aurobindo Pharma signs pact to acquire generic pharmaceutical firm TAD Italy

Aurobindo Pharma has announced that the company has entered into a strategic deal with TAD Italy, a generic company registered in Italy for acquisition of intellectual property and marketing authorizations.

The company has also acquired high profile OTC brands--Mapooro and Carmiooro--from TAD as a part of this deal.

This is the company's third acquisition in Europe, after buying Milpharm in UK and Pharmacin International BV, in Netherlands. However, no financial details were provided by the company.

The current acquisition will give Aurobindo an access to more than 70 ready to market products which will fast track company's entry into the Italian generic market.

Suven Life Sciences gets two product patent in Eurasia

India's Suven Life Sciences Limited has received two product patents in Eurasia for new chemical entities, used in the treatment of disorders associated with Neurodegenerative diseases. These patents are valid till 2023.

The patents are valid in all contracting countries like Armenia, Azerbaijan, Belarus, Kyrgyzstan, Kazakhstan, Moldova, Russia, Tajikistan and Turkmenistan.

The granted claims of the patents include the class of selective 5-HT compounds discovered by Suven and are being developed as therapeutic agents and are useful in the treatment of cognitive impairment associated with neuro-degenarative disorders like Attention deficient hyperactivity, Alzheimer's, Parkinson, Schizophrenia and Huntington's.

Sun Pharma Gets USFDA Nod To Market ‘Benzonatate’ In Indian Market

Leading drug manufacturer, Sun Pharmaceutical Industries has announced Sun Pharmaceutical Ind. Ltdthat it has got marketing authorization from the US Food and Drug administration (USFDA) for the abbreviated new drug application (ANDA) of its generic version of anti-cough drug ‘Benzonatate.’

In a declaration, the company said, “USFDA has granted approval for the abbreviated new drug application (ANDA) to market a generic version of Forest Labs Tessalon, Benzonatate capsules.”

Sun Pharmaceuticals gets approval for Fosphenytoin Sodium Injection

Gujarat based drug maker, Sun Pharmaceutical Industries Ltd has announced that USFDA has granted approval for the Abbreviated New Drug Application (ANDA) to market a generic version of Parke Davis's Cerebyx®, fosphenytoin sodium injection.

The fosphenytoin sodium injection USP, 50mg PE/mL, is therapeutically equivalent to Parke Davis's Cerebyx®, and is available in two packs 100 mg PE/2 mL and 500 mg PE/10 mL single dose vials.

The drug is mainly used for the control of generalized convulsive status epilepticus as well as for prevention and treatment of seizures occurring during neurosurgery. The injection has annual sales of approximately $ 15 million in the United States.

IOL Chemicals to invest Rs 300 crore by next year

IOL Chemicals and Pharmaceuticals, formerly known as Industrial Organics Industrial Organics LimitedLimited has announced that the company will invest around Rs 300 crore in its proposed extension plan during the next year.

The company has already acquired 65 acres of land for its backward and forward integration project.

Varinder Gupta, Chairman and Managing Director, IOL Chemicals said, "As the Rabiprazole is going off-patent, we are entering into this new segment and by investing Rs 300 crore to achieve a turnover of Rs 800 crore in the year 2010-11.”

Mantri Developers inks pact with Apollo Hospital

Mantri Developers Pvt. Limited has tied up with Apollo Hospitals Limited, the third largest health care group in the world, to provide quality health care services 24 x 7 through Telemedicine to residents of select Mantri homes, using contemporary state of the art technology.

Residents will now be able to harness the power of interconnectivity to obtain instant diagnosis from an expert panel of doctors associated with Apollo Hospitals.

This service will be first introduced in Mantri Espana, a Super Luxury residential complex located at Sarjapur, Outer Ring Road, Bangalore.

Mantri Espana is one of India’s most sought after residential developments offering luxury and lifestyle for the rich and famous.

Glenmark’s arm launches Nabumetone, Hydroxyzine Hcl in United States

India’s leading drugmaker Glenmark Pharmaceuticals Limited has announced that its US subsidiary, Glenmark Pharmaceuticals Inc. (GPI), has launched Nabumetone tablets and Hydroxyzine Hydrochloride tablets in the U.S. market.

Nabumetone is a non-steroidal anti-inflammatory drug, which is used to treat pain or inflammation caused by arthritis. While Hydroxyzine belongs to a group of medicines called sedating antihistamines and it is used in the treatment of anxiety.

Under the deal, Glenmark will exclusively market and distribute Nabumetone and Hydroxyzine Hydrochloride tablets while InvaGen will be responsible for their manufacture and supply.

Suven Life Sciences inks pact with Eli Lily; Stock surges 6%

Suven Life Sciences Limited has signed a second pact with Eli Lilly and company, a US based global pharmaceutical company, to collaborate on the pre-clinical research of molecules in the therapeutic area of central nervous system disorders (CNS).

Under the agreement, Suven will get research funding as well as potential discovery and development milestone payments in the range of USD 19 million to USD 23 million per candidate and potential royalties on net sales of any products that may be successfully commercialized from the collaboration.

Shilpa Medicare Gets Suitability Certificate To Sell ‘Oxaliplatin EP’ In Europe

Karnataka-based pharmaceuticals company Shilpa Medicare Ltd has received the certificate of Suitability (COS) of Monographs of the European Directorate for the Quality of Medicines (EDQM) to sell its cancer drug ‘Oxaliplatin EP’ in the European market.

The active pharmaceutical ingredient (API) Oxaliplatin EP is used for the treating colon and rectal cancer after prior treatment with fluoropyrimidines in mono-chemotherapy or any other linked treatment.

Shilpa Medicare was the first Indian company and fifth in the world to receive a COS from EDQM for Oxaliplatin EP.

During 2006, the worldwide sales for Oxaliplatin valued to US$ 1.9 billion. The annual growth rate of the drug stood at 28 percent.

LIC picks additional 2.3% stake in Orchid Chemicals

Chennai-based drug manufacturer Orchid Chemicals & Pharmaceuticals has announced that Life Insurance Corporation of India (LIC) has acquired an additional 2.3 per cent stake in the company.

With this stake acquisition, the holding of LIC has been increased to 7.82 per cent.

Last month, Orchid Chemicals had obtained approval from the US Food and Drug Administration (FDA) for its abbreviated new drug application (ANDA) for cefpodoxime proxetil tablets. The drug is available in 100 and 200 milligram strengths.

Orchid Chemicals is a good stock for long term investment. Investors having a long term investment capacity can consider taking position in the stock on declines.

Check out More news from Telecom Sector :: Pharmaceutical Sector :: Auto Sector :: Infrastructure :: Real Estate

Syndicate content